Hyaluronate Sodium 10 Mg/Ml Solution For Injection

Verify with FDA CVM →

32 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
32
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Hyaluronate Sodium 10 Mg/Ml Solution For Injection

Administration Routes

UnknownIntra-ArticularIntravenousIntrasynovial

Species Affected

Horse 18
Unknown 14

Most Affected Breeds

Unknown 14
Horse (unknown) 5
Quarter Horse 2
Warmblood - Dutch 2
Appaloosa 2
Standardbred (unspecified) 1
Tennessee Walking Horse 1
Belgian Draft, also called Brabant or Brabants trekpaard 1
Irish Cob (Tinker) 1
Paint 1

Most Reported Reactions

Underfilling, Vials 7
Underfilling, Container 6
Joint swelling 5
Lameness 4
Joint effusion 3
Containers, Damaged 3
Other abnormal test result NOS 3
Synovitis 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Stopper, abnormal 2
Hives (see also 'Skin') 2
Anaphylactoid reaction 2

Outcome Breakdown

Recovered/Normal
8 (44.4%)
Outcome Unknown
8 (44.4%)
Ongoing
2 (11.1%)

Data Summary

Metric Value
Total adverse event reports 32
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Hyaluronate Sodium 10 Mg/Ml Solution For Injection Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 32 adverse event reports referencing Hyaluronate Sodium 10 Mg/Ml Solution For Injection, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Hyaluronate Sodium 10 Mg/Ml Solution For Injection. Reported administration routes include Unknown, Intra-Articular, Intravenous, Intrasynovial. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Hyaluronate Sodium 10 Mg/Ml Solution For Injection reports are Horse (18 reports), Unknown (14 reports), with Horse accounting for the largest share. Within those species, Unknown (14), Horse (unknown) (5), Quarter Horse (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Hyaluronate Sodium 10 Mg/Ml Solution For Injection are Underfilling, Vials (7), Underfilling, Container (6), Joint swelling (5), Lameness (4). Of the 18 reports with a coded outcome, Recovered/Normal is the leading category at 44.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Hyaluronate Sodium 10 Mg/Ml Solution For Injection.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial